ADC Therapeutics announces $86.6M PIPE, Blue Owl loan amendment, HCR royalty amendment, and preliminary Q3 revenue

ADC Therapeutics SA

ADC Therapeutics agreed to sell 12,911,347 common shares at $1.4200 and pre-funded warrants for 48,088,653 shares at $1.32400 in an $86.6M private placement expected to close Oct. 22, 2026.
Blue Owl loan amendment prepays $70.0M principal, cuts outstanding term loans to $50.0M, eliminates the minimum liquidity covenant, and sets minimum trailing U.S. ZYNLONTA sales at $65.0M.
HCR Amendment eliminates the $150M change-of-control payment, allows royalty buyout for $525M by Dec. 31, 2029 or $750M after, and cuts permitted third-party debt to $50.0M.
HCR warrants for 9,834,776 shares cut from $3.8130 to $0.10; Lender Warrants for 527,295 shares cut from $8.30 to $1.00.
Preliminary Q3 ZYNLONTA net product revenues ~$21.0M; cash and equivalents $189.2M at Sept. 30, 2026; pro forma ~$196M after $76.3M PIPE net proceeds and $69.6M prepayment.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.